

Scientific Program

A. Overview

Keynote Lecture & Reception (Sunday, October 2, 2016)

Plenary Lectures and Symposia (October 3-6, 2016)

Poster Sessions (October 3-5, 2016)

Award and Poster Prizes (October 6, 2016)

The MDO2016 meeting will begin on Sunday, October 2 with registration from 13:00 to 18:00, opening and Keynote Lecture from 17:00 to 18:15, and a welcome reception mixer from 18:15 to 20:00. Conference events conclude on Thursday, October 6 with a closing session from 12:00 to 12:30 to present a **JBC Tabor Young Investigator Award**, and **MDO Best Poster Awards**.

	Sunday, October 2, 2016	Monday, October 3, 2016	Tuesday, October 4, 2016	Wednesday, October 5, 2016	Thursday, October 6, 2016
8:30		PL1: F. Gengurich-A half-century plus of P450: Successes, recent advances & future research	PL2: FJ Gonzalez-Influence of xenobiotic receptors and CYPs on metabolic disease	PL3: M. Ingelman-Sundberg-Genetic & epigenetic regulation of ADME & drug response	PL4: G. Perdew: Ah Receptor in homo sapiens facilitated resistance to PAH toxicity
9:00					
9:30		Coffee/Poster	Coffee/Poster	Coffee/Poster	Coffee/Poster
10:00		PS01: Advances in P450 structure & function	PS10: NRs in drug metabolism & diseases	PS13: Disease effects on drug metabolism	PS22: Emerging field of xenobiotic induced liver injury
10:30		PS02: P450 derived endo bioactive lipids	PS11: Transporters in drug development	PS14: Pharmacogenomics in oncology	PS23: Metabolism & neurotoxicity of pesticides &
11:00		PS03: Variability in drug metabolism & safety	PS12: Epoxide Hydrolases	PS15: Systems pharmacology & clinical translation	PS24: Herbal products: Insights from ADME
11:30					
12:00		Lunch/Symposium	Lunch/Symposium	Lunch/Symposium	Herb Tabor award from JBC + MDO
12:30					Poster prizes + closing remarks
13:00		Poster session	Poster session	Poster session	
13:30					
14:00		PS04: P450 genomics, functions & precision medicine		PS16: Metabolomics in drug disposition & response	
14:30		PS05: Non-P450 enzymes & oxidations		PS17: lncRNAs in liver functions & diseases	
15:00		PS06: New approaches in drug delivery & development		PS18: Catabolism disposition of antibody drug conjugate	
15:30		Coffee/Poster		Coffee/Poster	
16:00		PS07: Microsomal UGTs	Free afternoon Excursion to NAPA Valley (ticketed event)	PS19: Gut microbiota in drug metabolism & toxicity	
16:30		PS08: Enzymes and redox partners in the ER		PS20: Posttranscriptional regulation & posttranslational modulation	
17:00	Opening+ Keynote lecture	PS09: Biotran technique in the spotlight		PS21: CRISPR- New gene editing technologies in animal models	
17:30					
18:15					
18:30	Reception			Conference dinner (ticketed event)	
19:00					

B. Session Structure

Long Session (120 min)

25 + 5 min	25 + 5 min
25 + 5 min	20 + 5 min
25 + 5 min	20 + 5 min
25 + 5 min	20 + 5 min
25 + 5 min	10 + 5 min

Short Session (90 min)

25 + 5 min	20 + 5 min
25 + 5 min	20 + 5 min
25 + 5 min	20 + 5 min
25 + 5 min	10 + 5 min

Session Chairs are encouraged to inform/remind each invited speaker and oral presenter the time s/he has before the meeting and/or session starts, as outlined above.

C. Detail Program

Sunday, October 2, 2016

Opening

17:00 – 17:15 pm

Ballroom A/B/C

Aiming Yu (21st MDO Meeting Chair, Sacramento, CA, USA)

Magnus Ingelman-Sundberg (MDO Committee Chair, Stockholm, SE)

Keynote Lecture

17:15 – 18:15 pm

Ballroom A/B/C

Chair: Deanna Kroetz, UCSF, USA

Mechanism-Based Inactivation of Human Cytochrome P450s

Larry Wienkers, Amgen, San Francisco, CA, USA

Reception

18:15 – 20:00 pm

Alumni Center AGR Hall & Patio

Monday, October 3, 2016

Plenary Lecture 1

8:30 – 9:30 am

Ballroom A/B/C

Chair: Magnus Ingelman-Sundberg, Karolinska Institutet, Sweden

A Half-Century Plus of Cytochrome P450: Many Successes, Recent Advances, & A View to Future Research

F. Peter Guengerich, Vanderbilt University, Nashville, TN, USA

Coffee Break

9:30 – 10:00 am

Parallel Symposia

10:00 – 12:00 pm

PS01: Advances in Cytochrome P450 Structure and Function

Ballroom A

Chairs: *Emily E. Scott, University of Michigan, USA*

- **Structure of CYP3A5 and comparison with CYP3A4**
Eric Johnson, The Scripps Research Institute, USA
- **NMR and X-ray crystallography inputs in understanding CYP17A1 biochemistry and the design of improved inhibitors for prostate cancer**
Emily E. Scott, University of Michigan, USA
- **Studies of CYP2B selectivity: plasticity, peripheral pockets, pi bonds, and packrats**
James R. Halpert, University of Connecticut, USA
- **Substrate and inhibitor binding in CYP2D6 by NMR: How different is solution from the crystal?**
Thomas Pochapsky, Brandeis University, USA
- **Crystal Structures of CYP2C9, CYP2C9*3 and CYP2C9*30 in Complex with Multiple Losartan Molecules Reveal a Peripheral Binding Site and Alternate Active Site Orientations**
Manish Shah, University of Connecticut, USA

PS02: Cytochrome P450 Derived Endogenous Bioactive Lipids

Ballroom B

Chairs: *Darryl C. Zeldin, NIEHS/NIH & Craig R. Lee, University of North Carolina, USA*

- **The CYP Fatty Acid Metabolite 20-HETE and Brain Hypoperfusion: A Target for Drug Development?**
Samuel Poloyac, University of Pittsburgh, PA, USA
- **n-3 metabolites of CYP epoxygenases as mediators of cardioprotection**
John Seubert, University of Alberta, Canada
- **Cytochrome P450 derived epoxyeicosanoids as a therapeutic target in non-alcoholic fatty liver disease**
Craig Lee, University of North Carolina at Chapel Hill, USA
- **CYP-derived eicosanoids and macrophage function**
Darryl Zeldin, NIEHS/NIH, USA
- **Selected talk: Anti-inflammatory Omega-3 Endocannabinoid Epoxides**
Aditi Das, University of Illinois Urbana Champaign, USA

PS03: Variability in Drug Metabolism and Safety

Ballroom C

Chair: *Nico P.E. Vermeulen, Vrije University, The Netherlands*

- **Multistep bioactivation to and bioinactivation of reactive drug metabolites: CYP, NQO, UGT and GST mediated variability**
Nico P.E. Vermeulen, Vrije University, The Netherlands
- **Crosstalk of the aryl hydrocarbon receptor and β -catenin - signal integration by the CYP1A1 promoter**
Albert Braeuning, Federal Institute for Risk Assessment, Germany
- **Activity-imaging of cytochrome P450 1A in living systems**
Ling Yang, Dalian Institute of Chemical Physics, CAS, China
- **Brain CYP2D alters haloperidol-induced extrapyramidal symptoms in a rat model**

Rachel Tyndale, University of Toronto, Canada

- **Selected talk: Potential effects of gender on the expression of Phase I and Phase II metabolizing enzymes in human tissues**

Heidi Medford, Washington State University Health Sciences, USA

Lunch/Industry Symposium/Poster Session (Posters P001-P040)

12:00 – 14:00 pm

Conference Rooms A & B and Hallway

Parallel Symposia

14:00 – 15:30 pm

PS04: Cytochrome P450 Genomics, Functions and Precision Medicine Ballroom A

Chairs: F. Peter Guengerich, Vanderbilt University & Allan E. Rettie, University of Washington, USA

- **P450 pharmacogenomic testing for precision medicine**
Ann K. Daly, Newcastle University, UK
- **CYP2C9 and 4F gene variation in warfarin response & drug interactions**
Allan E. Rettie, University of Washington, USA
- **Human CYP4F22 in production of acylceramide for skin permeability barrier formation**
Akio Kihara, Hokkaido University, Japan

PS05: Importance and Function of Non-P450 Enzymes in Drug Oxidations Ballroom B

Chairs: Nina Isoherranen, University of Washington & Deepak Dalvie, Pfizer, USA

- **The emerging role of Non-P450 oxidoreductases in drug metabolism and toxicity**
Deepak Dalvie, Pfizer, USA
- **The function of FMO enzymes, lessons learned from transgenic mouse models**
Elizabeth A Shephard, University College London, UK
- **CES1 and CES2: Distribution, function and clinical significance**
Bhagwat Prasad, University of Washington, USA

PS06: New Approaches in Drug Delivery & Development Ballroom C

Chairs: Kit S. Lam, UC Davis School of Medicine, USA

- **Cancer Targeting and Nanodelivery**
Kit S. Lam, UC Davis School of Medicine, USA
- **An Integrated Model of Reactivity and Metabolism**
Tyler Hughes, Washington University in St. Louis, USA

- **Drug Target Residence Time Affects Drug *in vivo* Efficacy through Multiple Pathways**
Kin Sing Stephen Lee, UC Davis, USA

Coffee Break

15:30 – 16:00 am

Parallel Symposia

16:00 – 17:30 pm

PS07: UGTs - Functions and Clinical Importance

Ballroom A

Chairs: Michael H. Court, Washington State University, USA & Robyn Meech, Flinders University, Australia

- **Regulation of UGTs in cancer**
Robyn Meech, Flinders University, Australia
- **Human UGT1A pharmacogenetics: from bench to clinic**
Michael H. Court, Washington State University, USA
- **Using mouse genetic models to understand human UGT expression**
Robert Tukey, UCSD, USA

PS08: Organization of Drug-Metabolizing Enzymes and Their Redox Partners in the Endoplasmic Reticulum

Ballroom B

Chairs: Wayne Backes, LSU Health Sciences Center, USA & Yuji Ishii, Kyushu University, Japan

- **Functional interaction of UDP-glucuronosyltransferases and cytochrome P450 3A4: the domains of UGT involved in the interaction**
Yuji Ishii, Kyushu University, Japan
- **Direct Observation of Cytochrome P450 and Cytochrome P450 Reductase Interacting with Lipid Bilayers**
Jeff Jones, Washington State University, USA
- **P450 protein structure modulates their localization into specific lipid microdomains**
Wayne Backes, LSU Health Sciences Center, USA
- **Selected talk: Eavesdropping of crosstalk among drug-metabolizing cytochromes P450: Functional consequences of interactions between CYP2E1 and CYP2D6**
Dmitri Davydov, Washington State University, USA

PS09: Biotransformations & Technologies in the Spotlight

Ballroom C

Chairs: Hao-Jie Zhu, University of Michigan, USA

- **Unusual Aliphatic Oxidation and Carbon-carbon Bond Cleavage in the Sequential Metabolism of Olanexidine Catalyzed by Human Cytochrome P450 and Non-P450 Enzymes**

- Yiding Hu, Sanofi, USA*
- **In vitro Metabolism across Species of the Novel Late Cardiac Na⁺ Current Inhibitor Eleclazine**
Nevena Mollova, Gilead Sciences, Inc., USA
 - **Comparison of expression profiles of drug-metabolizing enzymes between human liver and the hepatic cell lines HepG2, Hep3B, and HuH7: a targeted quantitative proteomics study**
Hao-Jie Zhu, University of Michigan, USA
 - **Development of a Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Method for Imaging Tenofovir and Tenofovir-Diphosphate**
Dominique Figueroa, Johns Hopkins University, USA

Tuesday, October 4, 2016

Plenary Lecture 2

8:30 – 9:30 am

Ballroom A/B/C

Chair: Jeffrey Peters, The Pennsylvania State University

Nuclear Receptors at the Crossroads of Xenobiotic Metabolism and Metabolic Disease

Frank J. Gonzalez, NCI/NIH, Bethesda, MD, USA

Coffee Break

9:30 – 10:00 am

Parallel Symposia

10:00 – 12:00 pm

PS10: Nuclear Receptors in Drug Metabolism and Disease

Ballroom A

Chairs: Frank J. Gonzalez, NCI/NIH & Grace Guo, Rutgers University, USA

- **CAR & PXR as cell signal scaffolding proteins for drug targets**
Masahiko Negishi, NIEHS/NIH, USA
- **The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention**
Jeffrey Peters, The Pennsylvania State University, USA
- **A tale of bile acids and FXR in intestine-liver crosstalk**
Grace Guo, Rutgers University, USA
- **Nuclear receptors in the control of drug oxidation, toxicity and disease**
Qing-Yu Zhang, Wadsworth Center, New York State Department of Health, USA

- **Disrupting Hepatocyte *Cyp51* from Cholesterol Synthesis Decreases RORC Signaling and Leads to Progressive Liver Injury in the Developing Mouse**

Damjana Rozman, University of Ljubljana, Slovenia

PS11: Importance of Transporters in Drug Development

Ballroom B

Chairs: Yurong Lai, Bristol-Myers Squibb & Kathy Giacomini, UCSF, USA

- **Transporters as therapeutic targets**
Kathy Giacomini, UCSF, USA
- **The combination of in vitro experimental and modeling approaches to predict in vivo intracellular partitioning**
Yurong Lai, Bristol-Myers Squibb, USA
- **Importance of OCTs in drug transport**
Joanne Wang, University of Washington, USA
- **Renal transporters in xeno-endobiotic drug interactions**
Irene Lepist, Gilead Sciences, USA

PS12: Inhibition of Epoxide Hydrolase: Enzymes, targets and possible paths to clinic

Ballroom C

Chairs: Bruce D. Hammock, UC Davis & John D. Imig, Medical College of Wisconsin, USA

- **Results from FTIH/Experimental medicine clinical trials on a novel soluble epoxide hydrolase inhibitor, GSK2256294**
James F. Callahan, GlaxoSmithKline, USA
- **Soluble epoxide hydrolase inhibitors and polypharma approaches to treat renal fibrosis, hypertension and other disorders**
John D. Imig, Medical College of Wisconsin, USA
- **Epoxy eicosanoids and regulation of choroidal neovascularization in the eye: contribution of the soluble epoxide hydrolase**
Kip Connor, Harvard University, USA
- **Development of soluble epoxide hydrolase inhibitors to control pain in man and companion animals**
Bruce D. Hammock, UC Davis, USA

Lunch/Industry Symposium/Poster Session (Posters P041-080; **MDO Poster Competition)**

12:00 – 14:00 pm

Conference rooms A & B and hallway

Excursion to NAPA Valley (ticketed event)

14:00 – 20:00 pm.

Bus will depart from the Conference Center at 14:00 pm, and depart from NAPA Valley at 19:00 pm.

Wednesday, October 5, 2016

Plenary Lecture 3

8:30 – 9:30 am

Ballroom A/B/C

Chair: Uli Zanger, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Germany

Genetic and Epigenetic Regulation of ADME Gene Expression and Drug Response

Magnus Ingelman-Sundberg, Karolinska Institutet, Sweden

Coffee Break

9:30 – 10:00 am

Parallel Symposia

10:00 – 12:00 pm

PS13: Disease Effect on Drug Metabolism and Disposition

Ballroom A

Chairs: Wen Xie, University of Pittsburgh & Lauren Aleksunes, Rutgers University, USA

➤ **Regulation of Drug Transporters and Drug Disposition by Fatty Liver Disease**

Nathan Cherrington, University of Arizona, USA

➤ **Endobiotic and Xenobiotic Disposition in Pregnancy and Maternal Cholestasis**

Lauren Aleksunes, Rutgers University, USA

➤ **Role of Nuclear Receptors and MicroRNAs in the Regulation of Drug Metabolism by Inflammation**

Uli Zanger, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Germany

➤ **Regulation of Sulfotransferase by Local and Systemic Liver Injuries**

Wen Xie, University of Pittsburgh, USA

PS14: Pharmacogenomics in Oncology

Ballroom B

Chairs: Jatinder Lamba, University of Florida & Deanna Kroetz, UCSF, USA

➤ **Pharmacogenomics of microtubule targeting agents**

Deanna Kroetz, UCSF, USA

➤ **Integrative Omics approaches to advance outcome in AML**

Jatinder Lamba, University of Florida, USA

➤ **Assessing carcinogenesis and biomarkers in transgenic mice**

Xinxin Ding, SUNY College of Nanoscale Science and Engineering, USA

- **Next Generation Sequencing (NGS) for the identification of markers of drug response in cancer**
Cristina Rodríguez-Antona, Spanish National Cancer Center CNIO, Spain

PS15: Systems Pharmacology and Clinical Translation Ballroom C

Chairs: Chuang Lu, Biogen, USA; Sandy Pang, University of Toronto, Canada

- **Systems-pharmacological analysis of drug toxicities**
Masashi Honma/Hiroshi Suzuki, The University of Tokyo Hospital, Japan
- **Integrating DMPK data towards clinical trials – an industrial perspective**
Chuang Lu, Biogen, USA
- **Translation of in vitro biochemical data of vitamin A and retinoid metabolism to tissue specific changes in retinoid concentrations and signaling**
Nina Isoherranen, University of Washington, USA
- **Systems approach to explain the complex regulation of the vitamin D receptor on 1,25-dihydroxyvitamin D₃ kinetics and describe the pharmacodynamic responses**
Sandy Pang, University of Toronto, Canada

Lunch/Industry Symposium/Poster Session (Posters P081-P120)

12:00 – 14:00 pm

Conference rooms A & B and hallway

MDO Committee Meeting

12:00 – 13:30 pm

AGR Hall, Alumni Center

Parallel Symposia

14:00 – 15:30 pm

PS16: Metabolomics in Drug Disposition and Toxicology: Clinical and Translational Applications

Ballroom A

Chairs: Andrew D. Patterson, Pennsylvania State University, USA

- **Metabolic phenotyping of response to drug treatment: integrating metabolomics and genomics**
Oliver Fiehn, UC Davis, USA
- **Metabolomic applications to guide the mechanistic understanding of drug-induced liver injury**
Xiaochao Ma, University of Pittsburgh, USA
- **Metabolomics as a tool for translational science in xenobiotic disposition and toxicity**
Andrew D. Patterson, Pennsylvania State University, USA

- **Selected talk: Profiling Bioactivation Pathways of Antidepressant Duloxetine in Wild-type and Humanized Mice**
Feng Li, Baylor College of Medicine, USA

PS17: Roles of Long Non-Coding RNAs in Liver Development, Functions, and Diseases

Ballroom B

Chairs: Xiaobo Zhong & Li Wang, The University of Connecticut, USA

- **Liver lincRNAs responsive to hormones and foreign chemicals**
David Waxman, Boston University, USA
- **Long non-coding RNAs in liver growth, normal functions, and disease progress**
Xiaobo Zhong, The University of Connecticut, USA
- **LncRNA H19 in liver metabolic function**
Li Wang, The University of Connecticut, USA

PS18: Catabolism and Distribution of Antibody Drug Conjugate (ADC)

Ballroom C

Chairs: Cyrus Khojasteh & Donglu Zhang, Genentech, USA

- **Current understanding and challenges in the determination of ADME of ADCs**
Cyrus Khojasteh, Genentech, USA
- **A lysosomal transporter is required for non-cleavable linker ADC function**
Kevin Hamblett, Zymeworks, USA
- **Impact of payload drug metabolism on pharmacokinetics and efficacy of ADCs**
Dian Su, Genentech, USA
- **Linker immolation-directed ADC designs**
Donglu Zhang, Genentech, USA

Coffee Break

15:30 – 16:00 pm

Parallel Symposia

16:00 – 17:30 pm

PS19: Role of gut microbiota in drug metabolism and toxicology

Ballroom A

Chairs: Hyunyoung Jeong, University of Illinois – Chicago & Edward T. Morgan, Emory University, USA

- **The microbial pharmacist within us**
Peter Turnbaugh, UCSF, USA
- **RNA-Seq Quantification of Hepatic Drug-Processing Genes in Germ-Free Mice**
Curtis Klaassen and Julia Yue Cui, University of Washington, USA
- **Drugging the microbiome**

Aadra Bhatt/Matthew Redinbo, University of North Carolina at Chapel Hill, USA

PS20: Posttranscriptional Regulation and Posttranslational Modulation of Drug Metabolizing Enzymes

Ballroom B

Chairs: Philip Lazarus, Washington State University, USA & Tsuyoshi Yokoi, Nagoya University, Japan

- **Impact of RNA editing on microRNA function and drug-metabolizing enzymes**
Miki Nakajima, Kanazawa University, Japan
- **Role of epigenetics & alternate splicing in regulating UGT expression and activity**
Philip Lazarus, Washington State University, USA
- **ERAD of Hepatic Endoplasmic Reticulum (ER)-anchored Cytochromes P450 (P450s) and Cytosolic Tryptophan 2,3-dioxygenase (TDO): Structural Determinants**
M. Almira Correia, UCSF, USA
- **Selected talk: TGF- β 1 elevates BCRP expression in colorectal cancer through SMAD4/HOTAIR/miR-145 axis**
Wei-Peng Wang, Soochow University, China

PS21: New Gene Editing Technologies in Animal Models: Applications of CRISPR Tools

Ballroom C

Chairs: David Segal, UC Davis & Yin Hao, Massachusetts Institute of Technology, USA

- **Genome Engineering with CRISPR/Cas9 at the Dawn of the Golden Age**
David Segal, UC Davis, USA
- **In vivo genome editing: From proof-of-concept to therapeutic delivery**
Yin Hao, Massachusetts Institute of Technology, USA
- **Pancreatic Cancer Modeling with Somatic Genome Editing**
Monte Winslow, Stanford University, USA

Conference Banquet (ticketed event)

18:00 – 20:00 pm

Alumni Center AGR Hall

Thursday, October 6, 2016

Plenary Lecture 4

8:30 – 9:30 am

Ballroom A/B/C

Chair: Pamela Lein, UC Davis, USA

Molecular Evolution of the Ah Receptor in *Homo Sapiens* Facilitated Resistance to PAH Toxicity

Gary Perdew, Pennsylvania State University, University Park, PA, USA

Coffee Break

9:30 – 10:00 am

Parallel Symposia

10:00 – 12:00 pm

PS22: Emerging Field of Xenobiotic Drug Induced Liver Injury (DILI)

Ballroom A

Chairs: Xianglin Shi, University of Kentucky,, USA

- **MicroRNAs and oxidative stress in tumor angiogenesis and therapeutic resistance**
Bing-Hua Jiang, Thomas Jefferson University, USA
- **Prevention of Cr(VI)-carcinogenesis by natural compounds**
Xianglin Shi, University of Kentucky, USA
- **Flavin-Containing Monooxygenase 3 Function and Expression and its Potential Relationship to Adaptation to Acetaminophen-Induced Hepatotoxicity**
Gregory Smith/Jose Manautou, University of Connecticut, USA
- **Regulation of hepatic endoplasmic reticulum and P450 Enzymes Homeostasis by Autophagy**
Wenxing Ding, University of Kansas Medical Center, USA

PS23: Metabolism and Neurotoxicity of Pesticide Drugs and Persistent Organic Pollutants

Ballroom B

Chairs: Pamela Lein, UC Davis & James Olson, SUNY-Buffalo, USA

- **Neurotoxicity of organophosphorus pesticides in adolescents**
Diane Rohlman, The University of Iowa, USA
- **Metabolism of organophosphorus pesticides**
James Olson, SUNY-Buffalo, USA
- **Developmental neurotoxicity of polychlorinated biphenyls**
Pamela Lein, UC Davis, USA
- **Metabolism of polychlorinated biphenyls**
Hans Lehmler, The University of Iowa, USA

PS24: Holistic Efficacy of Herbal Products: Insights from ADME Gene Regulation

Ballroom C

Chairs: Huichang Bi, Sun Yat-Sen University & Jiang Zheng, Shenyang Pharmaceutical University, China

- **Transcriptional Activation of CYPs and UGTs by Natural Constituents From Traditional Chinese Medicines: Mechanisms and Applications**
Su Zeng, Zhejiang University, China

- **A systematic approach to identify clinically-relevant natural product-drug interactions**
Mary Paine, Washington State University, USA
- **Metabolic activation and hepatotoxicity of furanoterpene 8-epidiosbulbin E acetate**
Jiang Zheng, Shenyang Pharmaceutical University, China
- **Hepatoprotection with herbal *Schisandra* and active lignans: Insights from the modulation of metabolism**
Huichang Bi, Sun Yat-sen University, China
- **Selected talk: Potential CYP2C9 inhibition-mediated drug interactions by mangosteen extract and its active constituents in *in vitro/vivo* systems**
Young Hee Choi, Dongguk University, Republic of Korea

Awards & Closing

12:00 – 12:30 pm

Ballroom B

JBC Tabor Young Investigator Award

MDO Best Poster Awards

Introduction to MDO2018 Meeting

Closing Remarks